Drug treatment for spinal muscular atrophy type I

This review (2 RCTs; n=131) found limited evidence that intrathecal nusinersen probably prolongs ventilation-free and overall survival, and increases the proportion of patients achieving motor milestones, and classed as responders. The effect of riluzole is uncertain.

Source:

Cochrane Database of Systematic Reviews